Prescription Drug Importation

Protecting the US Drug Supply Chain

Caroline D. Juran, BSPharm, DPh (Hon), NABP Chairperson

Following the final rule approved by Trump Administration and published by Food and Drug Administration in 2020, states can now submit proposals to establish their own wholesale prescription drug importation program from Canada. While NABP understands the desire to decrease the costs of prescription drugs, states may face challenges while ensuring patient safety and securing the global supply chain. Continuing Chairperson Juran’s 2021 presidential initiative, NABP supports the boards of pharmacy and educates and protects the public about state drug importation plans. 

There are three areas of focus for the initiative:  

  • providing guidance to state and federal governments and other policy makers on the risks associated with prescription drug importation and the necessary regulatory oversight process to help mitigate those risks;  
  • working with state and federal regulators to implement the Drug Supply Chain Security Act (DSCSA), including providing education and other tools to regulators and supply chain participants to assist in implementation; and  
  • educating the public about the risks associated with purchasing prescription drugs from unknown sources online and through social media.   

Learn More

Increasing awareness about state importation programs is necessary to maintain patient safety. More information about prescription drug importation can be found in the below resources.